Lepu Biopharma Co (2157.HK) Stock Price

Lepu Biopharma Co., Ltd. generates revenue through the development and commercialization of oncology therapeutics, including antibody drug conjugate (ADC), oncolytic virus, and immunotherapy products at clinical and pre-clinical stages. The company's major pipeline assets, MRG003, MRG002, HX008, and LP002, are sold domestically in China via dedicated sales forces and internationally through partnerships. Strategic collaborations strengthen in-house R&D and manufacturing capabilities, supporting the commercialization of its pipeline products. The firm focuses on tumor candidate drugs, targeting both domestic and international markets with its key clinical-stage drug candidates. Lepu Biopharma's revenue streams come from the sale of its pipeline products, with MRG003, MRG002, HX008, and LP002 being the primary assets driving commercialization. The company leverages in-house manufacturing and strategic partnerships to expand its market reach, selling products in China through dedicated sales and marketing teams and internationally via partnerships. Its oncology-focused portfolio includes antibody drug conjugate (ADC), oncolytic virus, and immunotherapy products, which are developed through internal R&D and collaborations. The company's business model centers on combining in-house research and development with strategic collaborations to develop a market differentiating pipeline. Products like MRG003, MRG002, HX008, and LP002 are commercialized domestically in China and internationally through partnerships, targeting both the domestic and global oncology markets. Lepu Biopharma's revenue is derived from the sale of these pipeline assets, with a focus on tumor candidate drugs in clinical and pre-clinical stages.